Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; Staccato Study Group. Ananworanich J, et al. Antivir Ther. 2005;10(6):761-7. Antivir Ther. 2005. PMID: 16218176 Clinical Trial.
Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K. Puthanakit T, et al. Among authors: ananworanich j. J Antimicrob Chemother. 2009 Nov;64(5):1080-6. doi: 10.1093/jac/dkp322. Epub 2009 Sep 2. J Antimicrob Chemother. 2009. PMID: 19729375 Clinical Trial.
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
Ramautarsing RA, van der Lugt J, Gorowara M, Wongsabut J, Khongpetch C, Phanuphak P, Ananworanich J, Lange JM, Burger DM, Ruxrungtham K, Avihingsanon A. Ramautarsing RA, et al. Among authors: ananworanich j. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):55-8. doi: 10.1097/QAI.0b013e31823ba736. J Acquir Immune Defic Syndr. 2012. PMID: 22027875 Clinical Trial.
Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
Avihingsanon A, van der Lugt J, Singphore U, Gorowara M, Boyd M, Ananworanich J, Phanuphak P, Burger D, Ruxrungtham K. Avihingsanon A, et al. Among authors: ananworanich j. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1170-6. doi: 10.1089/AID.2011.0247. Epub 2012 Mar 6. AIDS Res Hum Retroviruses. 2012. PMID: 22250979
Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
Ananworanich J, Gorowara M, Avihingsanon A, Kerr SJ, van Heesch N, Khongpetch C, Uanithirat A, Hill A, Ruxrungtham K, Burger DM; HIV-NAT 127 Study Team. Ananworanich J, et al. Antimicrob Agents Chemother. 2012 Apr;56(4):1892-8. doi: 10.1128/AAC.05694-11. Epub 2012 Jan 17. Antimicrob Agents Chemother. 2012. PMID: 22252825 Free PMC article. Clinical Trial.
401 results